| Imfinzi (durvalumab) / AstraZeneca |
ACTRN12621000586819p: TROG 20.01 CHEST RT: Chemotherapy and Immunotherapy in extensive stage small cell lung cancer with thoracic radiotherapy |
|
|
| Not yet recruiting | 2 | 35 | | | Trans Tasman Radiation Oncology Group, Astra Zeneca | Cancer; Extensive Stage Small Cell Lung Cancer; Lung Cancer | | | | |
ACTRN12623000657628: Investigating the impact of adding olaparib, or olaparib and durvalumab together, to standard chemotherapy before surgery in young, pre-menopausal women with HER2-negative breast cancer. |
|
|
| Recruiting | 2 | 56 | | | Breast Cancer Trials, National Health and Medical Research Council - MRFF RCRDUN | Breast Cancer | | | | |
DATE study, jRCTs031190117: Phase II study of durvalumab (MEDI4736) maintenance therapy immediately after completion of chemoradiotherapy for unresectable locally advanced (stage III) non-small cell lung cancer (TORG1937/) |
|
|
| Completed | 2 | 47 | Japan | carboplatin - Generic mfg., cisplatin - Generic mfg., Teysuno (gimeracil/oteracil/tegafur) - Nordic Group, Otsuka, docetaxel - Generic mfg., paclitaxel - Generic mfg., vinorelbine tartrate - Generic mfg., Imfinzi (durvalumab) - AstraZeneca | Nippon Medical School Hospital, AstraZeneca | Untreated locally advanced stage III NSCLC | | | | |
2020-004859-32: Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations Olaparib y durvalumab (MEDI4736) en pacientes con cáncer de páncreas metastásico y alteraciones en los genes de reparación de daño en el ADN |
|
|
| Ongoing | 2 | 40 | Europe | Concentrate for solution for infusion, Film-coated tablet, IMFINZI, Lynparza | Grupo de Tratamiento de los Tumores Digestivos (TTD), Astra Zeneca | Metastatic pancreatic cancer and DNA Damage Repair genes alterations Cáncer de páncreas metastásico y alteraciones en los genes de reparación de daño en el ADN, Metastatic pancreatic cancer Cáncer de páncreas metastásico, Diseases [C] - Cancer [C04] | | | | |
ACTRN12619000097145: Combined radiotherapy and immunotherapy for men with early metastatic prostate cancer not on hormone therapy |
|
|
| Recruiting | 2 | 30 | | | Northern Sydney Local Health District, Royal North Shore Hospital | Prostate Cancer | | | | |
Dolphin, jRCT2080224763: Phase II study of Durvalumab (MEDI4736) Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients( study: WJOG11619L) |
|
|
| Completed | 2 | 35 | Japan | Imfinzi (durvalumab) - AstraZeneca | Kobe University Hospital, AstraZeneca K.K. | Non-small cell lung cancer | | | | |
NEJ045A, jRCTs031200319: A Phase II Study of Carboplatin + Etoposide + Durvalumab Therapy for Patients With Advanced Small Cell Lung Cancer With Poor PS (PS 2-3) |
|
|
| Active, not recruiting | 2 | 56 | Japan | Imfinzi (durvalumab) - AstraZeneca, carboplatin - Generic mfg., etoposide IV - Generic mfg. | Niigata University Medical and Dental Hospital | Extensive disease small cell lung cancer | | | | |
ACTRN12621000507886: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 15 substudies 33-34: Durvalumab plus acalabrutinib |
|
|
| Recruiting | 2 | 32 | | | The University of Sydney, Office for Health and Medical Research, Leukaemia Foundation , Tour de Cure | Cancer, High grade B cell lymphoma | | | | |
ACTRN12621000586819: TROG 20.01 CHEST RT: Chemotherapy and Immunotherapy in extensive stage small cell lung cancer with thoracic radiotherapy |
|
|
| Recruiting | 2 | 35 | | | Trans Tasman Radiation Oncology Group, Astra Zeneca | Cancer, Extensive Stage Small Cell Lung Cancer, Lung Cancer | | | | |
| Active, not recruiting | 2 | 446 | Europe, Canada, Japan, US, RoW | MEDI4736 | AstraZeneca | Non-Small Cell Lung Cancer | 06/16 | 02/25 | | |
|
|
2014-000814-73: National Lung Matrix: Multi-drug Phase II trial in Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 620 | Europe | Palbociclib, Xalkori, Selumetinib, Docetaxel, Taxotere, Taxceus, Sitravatinib, AZD4547, AZD2014, PD 0332991, PF-02341066, AZD6244, ARRY 142886, MEDI4736, AZD5363, AZD9291, MGCD516, Tablet, Capsule, Concentrate for solution for infusion, Lyophilisate for solution for infusion, Xalkori, Docetaxel, Taxotere, Taxceus | University of Birmingham, AstraZeneca, Pfizer, Cancer Research UK | Metastatic or locally advanced non-small cell lung cancer (NSCLC), Commonest form of lung cancer, non-small cell lung cancer (NSCLC), Diseases [C] - Cancer [C04] | | | | |
2016-001688-35: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors Studio in aperto, randomizzato, di fase 2 con l¿anticorpo anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, da solo o in combinazione con Tremelimumab, in pazienti con neoplasie germinali avanzate e ricadute alla chemioterapia |
|
|
| Ongoing | 2 | 120 | Europe | MEDI4736, Tremelimumab, MEDI4736, MEDI1123, Solution for infusion, Concentrate for solution for infusion | FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", Astra Zeneca | Advanced and relapsed germ cell tumors Neoplasie germinali in fase metastatica ricadute o in progressione dopo trattamento chemioterapico di seconda o terza linea., Germ cell Tumor Neoplasie germinali in fase metastatica ricadute o in progressione dopo trattamento chemioterapico di seconda o terza linea., Diseases [C] - Cancer [C04] | | | | |
2016-004524-38: Treatment of patients with HIV-1 and advanced solid tumors with Durvalumab Tratamiento de pacientes con HIV-1 y tumores sólidos avanzados con Durvalumab |
|
|
| Ongoing | 2 | 20 | Europe | MEDI4736, Concentrate for solution for infusion | Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón), Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón) | advanced solid tumors in HIV-1 infected patients tumores sólidos avanzados en pacientes infectados por VIH-1, advanced tumors in patients infected by human immunodeficiency virus tumores avanzados en pacientes infectados por el virus de la inmunodeficiencia humana, Diseases [C] - Cancer [C04] | | | | |
NCT02250326 / 2014-001105-41: Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer |
|
|
| Completed | 2 | 240 | Europe, Canada, US | nab-paclitaxel IV, Abraxane, ABI-007, CC-486, Oral AZA, Oral azacitidine, Duravalumab | Celgene | Carcinoma, Non-Small-Cell Lung | 07/17 | 08/23 | | |
| Completed | 2 | 18 | RoW | Durvalumab,Tremelimumab, Experimental group | Seoul National University Hospital, Korean Cancer Study Group | HNSCC, Head and Neck Neoplasms | 02/19 | 06/21 | | |
| Completed | 2 | 64 | Europe, US, RoW | Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy | AstraZeneca | Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma | 02/18 | 03/23 | | |
|
2017-001664-37: A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC Studio randomizzato di fase 2 di confronto tra immunoterapia e chemioterapia nel trattamento del paziente anziano |
|
|
| Ongoing | 2 | 240 | Europe | CARBOPLATINO, Durvalumab, Tremelimumab, Gemcitabina, Pemetrexed, [CARBOPLATINO], [Durvalumab], [Tremelimumab], [Gemcitabina], [Pemetrexed], Concentrate for solution for infusion, Solution for infusion, CARBOPLATINO SANDOZ GMBH - 10MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 60ML, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 15 ML, ALIMTA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO | ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, AstraZeneca S.p.A. | patients with advanced NSCLC pazienti con NSCLC avanzato, patients with advanced non-small cell lung cancer pazienti con tumore del polmone non a piccole cellule avanzato, Diseases [C] - Cancer [C04] | | | | |
2017-004213-24: A RANDOMIZED TRIAL OF DURVALUMAB AND TREMELIMUMAB ¿ PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK, METASTATIC (STAGE IV) SQUAMOUS OR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) Studio randomizzato di Duravalumab e Tremelimumab ¿ Chemioterapia a base di platino in pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso |
|
|
| Not yet recruiting | 2 | 300 | Europe | Durvalumab, Tremelimumab, Gemcitabina, CARBOPLATINO, Pemetrexed, Durvalumab, Tremelimumab, Gemcitabina, CARBOPLATINO, Pemetrexed, Solution for infusion, Concentrate for solution for infusion, GEMCITABINA ACCORD HEALTHCARE - 1 G POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 50 ML, CARBOPLATINO AHCL - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 45 ML, ALIMTA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO | ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, Canadian Cancer Trials Group (CCTG) | Patients with high-risk, metastatic (Stage IV) squamous or non-squamous NSCLC. Pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso., Patients with high-risk, metastatic (Stage IV) squamous or non-squamous NSCLC. Pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso., Diseases [C] - Cancer [C04] | | | | |
2016-003175-22: Trial with immunotherapie for patients with locally advanced head and neck cancer Studie zur Immuntherapie bei Patienten mit lokal fortgeschrittenen Tumoren des Kopf-Hals Bereichs |
|
|
| Ongoing | 2 | 120 | Europe | Durvalumab, Tremelimumab, MEDI4736, Solution for infusion | Charite Universitätsmedizin Berlin, Charité Comprehensive Cancer Center, AstraZeneca GmbH | NON-RESECTABLE LOCALLY ADVANCED HPV NEGATIVE HNSCC, locally advanced head and neck cancer Fortgeschrittene Kopf-Hals Tumoren, Diseases [C] - Cancer [C04] | | | | |
2017-000577-36: DUTRELASCO trial (DUrvalumab with or without Tremelimumab in REsectable Locally Advanced Squamous cell Carcinoma of the Oral cavity) |
|
|
| Not yet recruiting | 2 | 20 | Europe | Tremelimumab, Durvalumab (Medi 4736), Medi 4736, Solution for infusion, Durvalumab (Medi 4736) | University Hospitals Leuven, University Hospitals Leuven, Astra Zeneca | resectable, locally advanced squamous cell carcinoma of the oral cavity, resectable, locally advanced squamous cell carcinoma of the oral cavity, Diseases [C] - Cancer [C04] | | | | |
2017-003226-33: Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC |
|
|
| Ongoing | 2 | 120 | Europe | Durvalumab, Tremelimumab, MEDI4736, MEDI1 123, Concentrate for solution for infusion | Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. Jürgen Schüttler, Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg | Locally advanced head and neck squamous cell carcinoma (HNSCC), Head and neck cancer, Diseases [C] - Cancer [C04] | | | | |
2017-003159-44: Durvalumab plus tremelimumab and radiotherapy for localized muscle invasivebladder cancer treatment Durvalumab más tremelimumab y radioterapia concomitante para el tratamiento del carcinoma de vejiga músculo-invasivo localizado |
|
|
| Ongoing | 2 | 32 | Europe | Durvalumab, Tremelimumab, MEDI4736, Tremelimumab, Solution for infusion | Spanish Oncology Genitourinary Group, AstraZeneca | Localized muscle invasive bladder cancer Carcinoma de vejiga músculo-invasivo localizado, Invasive bladder cancer Cáncer invasivo de vejiga, Diseases [C] - Cancer [C04] | | | | |
2018-002100-13: A study with patients with non-muscle-invasive bladder cancer that will receive Durvalumab with direct injection in bladder and at the same time some specific molecules named biomarkers will be investigated. Μια μελέτη με ασθενείς με μη μυοδιηθητικό καρκίνο της ουροδόχου κύστης που θα λάβουν το Durvalumab με απευθείας ένεση στην ουροδόχο κύστη και παράλληλα θα μελετηθούν και κάποια ειδικά μόρια που λέγονται βιοδείκτες. |
|
|
| Not yet recruiting | 2 | 39 | Europe | Durvalumab, MEDI14736, Concentrate for solution for infusion | Hellenic GenitoUrinaty Cancer Group (HGUCG), Hellenic GenitoUrinaty Cancer Group (HGUCG) | Non-muscle-invasive bladder cancer Mη μυοδιηθητικός καρκίνος της ουροδόχου κύστης, Bladder cancer that does not invade the muscular part of the bladder Καρκίνος ουροδόχου κύστης που δεν διηθεί το μυϊκό τμήμα της κύστης, Diseases [C] - Cancer [C04] | | | | |
ACTRN12617001468314: Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 2 | 80 | | | NHMRC Clinical Trials Centre, Canadian Cancer Trials Group | Lung Cancer Metastatic | | | | |
2018-002014-13: Evaluation of the efficacy of a combinaison treatment based upon immunotherapy + chemotherapy to treat patient with a stomach cancer Évaluation de l'efficacité d'un traitement combiné immunothérapie + chimiothérapie pour traiter les patients atteints d'un cancer de l'estomac. |
|
|
| Not yet recruiting | 2 | 94 | Europe | MEDI4736, tremelimumab, MEDI4736, MEDI1123, Concentrate for solution for infusion | Fédération Francophone de Cancérologie Digestive, Astra Zeneca | Advanced gastric or gastro-oesophageal junction adenocarcinoma Adénocarcinome gastrique ou de la jonction oeso-gastrique avancé, Advanced gastric or gastro-oesophageal junction adenocarcinoma Adénocarcinome gastrique ou de la jonction oeso-gastrique avancé, Diseases [C] - Cancer [C04] | | | | |
2018-001976-39: Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck Essai évaluant la tolérance et la sécurité du durvalumab associé à une radiothérapie pour le traitement des cancers de la tête et du cou |
|
|
| Ongoing | 2 | 73 | Europe | MEDI4736, MEDI4736, Concentrate for solution for infusion | GORTEC, GORTEC, AstraZeneca | Untreated Squamous cell carcinoma : Oral cavity, oropharynx, hypopharynx or larynx Carcinome épidermoïde non traité: Cavité orale, oropharynx, hypopharynx ou larynx, Untreated squamous cell carcinoma of the head and neck Carcinome épidermoïde de la tête et du cou non traité, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 999 | Europe | AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Standard maintenance for squamous NSCLC, Pemetrexed, ALIMTA, Durvalumab, savolitinib, Olaparib, LYNPARZA | UNICANCER, Intergroupe Francophone de Cancerologie Thoracique, Fondation ARC, AstraZeneca | Non-small Cell Lung Cancer Metastatic | 12/18 | 12/23 | | |
2018-003115-21: A phase II trIal for combination therapy with durvaLumab anD tremelimumAb in patients with metastatic solid tumors |
|
|
| Not yet recruiting | 2 | 108 | Europe | durvalumab, Tremelimumab, MEDI4736, Solution for infusion | Gustave Roussy, AstraZeneca | Metastatic colorectal adenocarcinoma (without microsatellite instability (not MSI)), triple negative breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma and human papilloma virus (HPV) negative head and neck squamous cell carcinoma with detection of ≥ 5 somatic mutations per megabase measured by whole exome sequencing in a tumor sample of the patient, Metastatic colorectal adenocarcinoma, breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma and HPV negative head and neck squamous cell carcinoma, Diseases [C] - Cancer [C04] | | | | |
2017-000580-32: Cabozantinib plus Ddurvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm trial Studio di fase 2, in aperto, monocentrico, a singolo braccio con cabozantinib più durvalumab in pazienti affetti da carcinoma vescicale con istologia urotreliale e non uroteliale in fase avanzata precedentemente trattati con chemioterapia |
|
|
| Not yet recruiting | 2 | 122 | Europe | CABOMETYX, Durvalumab, [CABOMETYX], [Durvalumab], Film-coated tablet, Lyophilisate for solution for injection, CABOMETYX, Imfinzi | FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", IPSEN S.p.A., AstraZeneca S.p.A. | Patients with metastatic urothelial carcinoma who have relapsed after =1 chemotherapy regimen Pazienti con carcinoma uroteliale metastatico che sono ricaduti dopo almeno una linea di chemioterapia, Patients with metastatic urothelial carcinoma Pazienti con carcinoma uroteliale metastatico, Diseases [C] - Cancer [C04] | | | | |
2017-003780-35: Phase II Study: Second line therapy in patients with non small cell lung cancer (NSCLC) with Durvalumab plus Tremelimumab after platinum based chemotherapie compared with platinum based chemotherapy alone Phase II Studie: Zweitlinientherapie in Patienten mit nicht-kleinzelligem Lungenkarzinom (NSCLC) mit Durvalumab plus Tremelimumab nach Platinum-basierter Chemotherapie verglichen mit alleiniger Platinum-basierter Chemotherapie |
|
|
| Not yet recruiting | 2 | 196 | Europe | Durvalumab, Tremelimumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Gemcitabine, MEDI4736, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for infusion | AIO-Studien-gGmbH, AstraZeneca GmbH | Non-small cell lung cancer stage IV Nicht-kleinzelliges Bronchialkarzinom Stadium IV, Lungcancer Lungenkrebs, Diseases [C] - Cancer [C04] | | | | |
2018-002077-21: PHOENIX: A trial to look for markers in the tumour cells and blood which signal that trial drugs are working in a patient with tripe negative breast cancer, for whom upfront chemotherapy has not provided the maximum expected benefit |
|
|
| Not yet recruiting | 2 | 81 | Europe | AZD6738 Film-Coated Tablet, Olaparib (Lynparza), Durvalumab, AZD6738, AZD2281, MEDI4736, Film-coated tablet, Tablet, Concentrate for solution for infusion, Olaparib (Lynparza) | The Institute of Cancer Research, AstraZeneca UK Ltd, Cancer Research UK | Triple Negative Breast Cancer, Triple Negative Breast Cancer, Diseases [C] - Cancer [C04] | | | | |
2018-003027-11: A prospective, multi-center, open-label, single-arm, two- step phase II study of DURvalumab (MEDI4736) in patients WIth poor performance status as first-liNe treatment for advanced urothelial cancer: the DURWIN trial Studio prospettico, multicentrico, in aperto, a singolo braccio, in due fasi di durvalumab (MEDI4736) in pazienti con scarso performance status, come trattamento di prima linea per il carcinoma uroteliale avanzato: lo studio DURWIN |
|
|
| Ongoing | 2 | 48 | Europe | DURVALUMAB, [MEDI4736], Concentrate for solution for infusion | CONSORZIO ONCOTECH, AstraZeneca Spa | Patients aged 18 years or older with histologically or cytologically documented locally advanced (on the TNM staging system, T4b and any N; or any T and N2–3) or metastatic (M1, stage IV) urothelial carcinoma (including of the renal pelvis, ureter, urinary bladder, or urethra) who are eligibile to receive first-line systemic treatment and are judged to be ineligible for cisplatin treatment because of ECOG performance status= 2 Pazienti =18 anni con carcinoma uroteliale localmente avanzato (sulla base del sistema di stadiazione TNM, T4b e qualsiasi N; o qualsiasi T e N2-3) o metastatico (M1, stage IV) istologicamente o citologicamente documentato; che sono eleggibili per un trattamento sistemico di prima linea e sono stati giudicati non eleggibili ad un trattamento a base di cisplatino a causa di uno ECOG performance status= 2, Patients wIth poor performance status as first-line treatment for advanced urothelial cancer Pazienti con scarso performance status come trattamento di prima linea per il carcinoma uroteliale avanzato: lo studio DURWIN, Diseases [C] - Cancer [C04] | | | | |
2018-004758-39: STUDY OF CAPECITABINE PLUS CONCOMITANT RADIATION THERAPY FOLLOWED BY DURVALUMAB AS PREOPERATIVE TREATMENT IN PATIENTS WITH RECTAL CANCER STUDIO CLINICO DEL TRATTAMENTO PREOPERATORIO CON CAPECITABINA E RADIOTERAPIA SEGUITE DA DURVALUMAB IN PAZIENTI CON TUMORE DEL RETTO |
|
|
| Not yet recruiting | 2 | 60 | Europe | Durvalumab, [MEDI4736], Concentrate for solution for infusion | AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA, AstraZeneca S.p.A., AUSL della Romagna | Locally advanced (T3-4 N0-1) rectal cancer. Carcinoma del retto localmente avanzato, T3-4 e N0-1., Rectal cancer Tumore del retto, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 65 | Europe, Canada, US, RoW | Oral Azacitidine, CC-486, Durvalumab, Imfinzi, MEDI4736 | Celgene | Myelodysplastic Syndromes | 06/19 | 09/23 | | |
2018-004835-56: Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer Estudio en fase II de Durvalumab (MEDI4736) más terapia total neoadyuvante en el cáncer rectal localmente avanzado |
|
|
| Ongoing | 2 | 58 | Europe | Durvalumab, MEDI4736, Solution for infusion | Grupo español mutidisciplinar en cáncer digestivo (GEMCAD), AstraZeneca | Locally advanced rectal cancer Cáncer rectal localmente avanzado, Locally advanced rectal cancer Cáncer rectal localmente avanzado, Diseases [C] - Cancer [C04] | | | | |
| Not yet recruiting | 2 | 67 | Europe | Durvalumab, MEDI4736, Concentrate for solution for infusion, Imfinzi | IFCT, IFCT, AstraZeneca | Patient with a non small cell lung cancer and a poor general status, Lung cancer in patient with a poor general condition, Diseases [C] - Cancer [C04] | | | | |
2019-000308-13: Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virus |
|
|
| Not yet recruiting | 2 | 180 | Europe | Durvalumab, Cisplatin, MEDI4736, Concentrate for solution for infusion | European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Canadian Cancer Trials Group (CCTG), AstraZeneca | Oropharyngeal Squamous Cell Carcinoma, Cancer of the Head and Neck, Diseases [C] - Cancer [C04] | | | | |
2019-001641-40: Study of advacned resectable head and neck cancer with immunotherapy and radiotherapy before surgery Studio sul trattamento del tumore della testa/collo avanzato ma operabile con immunoterapia e radioterapia prima della chirurgia |
|
|
| Not yet recruiting | 2 | 14 | Europe | IMFINZI, [DURVALUMAB], Lyophilisate for solution for injection, Imfinzi | ISTITUTI FISIOTERAPICI OSPITALIERI, Astra Zeneca | Advanced resectable head and neck tumor Tumore della testa/collo avanzato ma resecabile, Resectable head and neck cancer Tumore della testa e del collo operabile, Diseases [C] - Cancer [C04] | | | | |
2018-004490-27: A multicentric Phase II, open-label study evaluating the efficacy of the combination of hypofractionated stereotactic radiation therapy with the anti-PDL1 immune checkpoint inhibitor Durvalumab in NSCLC patients with 1 to 4 Brain Metastases. Etude de phase II multicentrique en ouvert évaluant l’efficacité de l’association d’une radiothérapie hypofractionnée en conditions stéréotaxiques et de l’inhibiteur de checkpoint immunitaire anti-PDL1 durvalumab chez des patients porteurs de 1 à 4 métastases cérébrales de CBNPC. |
|
|
| Not yet recruiting | 2 | 100 | Europe | DURVALUMAB, MEDI4736, Concentrate for solution for infusion, IMFINZI® | INSTITUT CLAUDIUS REGAUD | Non-small cell lung cancer Cancer bronchique non à petites cellules, Non-small cell lung cancer Cancer bronchique non à petites cellules, Diseases [C] - Cancer [C04] | | | | |
2018-003645-41: Phase II trial evaluating the efficacy of durvalumab (MEDI4736) as second-line therapy in Non- Small-Cell Lung Cancer patients receiving concomitant steroids Studio di fase II volto a valutare l’efficacia del Durvalumab nei pazienti con tumore al polmone non a piccole cellule che assumano contemporaneamente steroidi |
|
|
| Ongoing | 2 | 84 | Europe | Durvalumab, Prednisone, [MEDI4736], [Prednisone], Concentrate for solution for infusion, Tablet | FONDAZIONE RICERCA TRASLAZIONALE, Astrazeneca | Non- Small-Cell Lung Cancer Carcinoma al polmone non a piccole cellule, Non- Small-Cell Lung Cancer Tumore al polmone non a piccole cellule, Diseases [C] - Cancer [C04] | | | | |
2018-003011-22: A phase II trial assessing the efficacy (how well the treatment works), safety and tolerability (side effects of treatment) of the antibody drug durvalumab, administered together with standard chemotherapy and radiotherapy Ensayo de fase II que evalúa la eficacia (qué tan bien funciona el tratamiento), seguridad y tolerabilidad (efectos secundarios del tratamiento) del anticuerpo durvalumab, administrado junto con quimioterapia y radioterapia estándar. |
|
|
| Not yet recruiting | 2 | 96 | Europe | durvalumab, [MEDI4736], Concentrate for solution for infusion, IMFINZI | ETOP (European Thoracic Oncology Platform), ETOP IBCSG Partners Foundation, EUROPEAN THORACIC ONCOLOGY PLATFORM, AstraZeneca, ASTRA ZENECA | Synchronous oligo-metastatic Non-Small Cell Lung Cancer (NSCLC) Cáncer de pulmón no microcítico sincrónico oligometastásico, a type of lung cancer that is called Non-Small Cell Lung Cancer (NSCLC) that spread in some parts of the body (oligo-metastatic) un tipo de cáncer de pulmón que se llama cáncer de pulmón no microcítico (CPNM) que se disemina en algunas partes del cuerpo (oligo-metastásico), Diseases [C] - Cancer [C04] | | | | |
2018-004778-81: A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care |
|
|
| Not yet recruiting | 2 | 50 | Europe | Durvalumab, Tremelimumab, Solution for infusion, IMFINZI | Institut für Klinische Krebsforschung IKF GmbH, AstraZeneca GmbH, BTG International Ltd. | Intrahepatic Biliary Tract Carcinoma, Intrahepatic Biliary Tract Cancer, Diseases [C] - Cancer [C04] | | | | |
2019-000058-77: Comparison of two treatment arms of patients with non-small cell lung cancer. Patients of one arm receive the authorized infusion Durvalumab after chemotherapy, chemotherapy with radiotherapy and optional resection. Patients in the second treatment arm receive Durvalumab from the beginning, in parallel with standard therapy. |
|
|
| Not yet recruiting | 2 | 90 | Europe | Durvalumab, MEDI4736, Concentrate for solution for infusion, IMFINZI® | University Hospital Essen, Astra Zeneca | non-small cell lung cancer stages IIIA (N2) and selected resectable stages IIIB, Lung cancer, stages IIIA and IIIB, Diseases [C] - Cancer [C04] | | | | |
ACTRN12616001019493: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum: durvalumab plus tremelimumab |
|
|
| Completed | 2 | 112 | | | University of Sydney, Office for Health and Medical Research | Cancer | | | | |
| Completed | 2 | 123 | Europe | Durvalumab, MEDI4736, Tremelimumab, CP-675,206 | Grupo Espanol de Tumores Neuroendocrinos | Neuroendocrine Tumors, Neuroendocrine Neoplasm of Lung | 11/19 | 05/22 | | |
2016-005225-37: A randomized trial assessing the addition of the immunotherapeutic drugdurvalumab after high dose radiation in patients with localized early stageNon-small cell lung cancer Avoin satunnaistettu vaiheen II tutkimus, jossa durvalumabia annetaan stereotaktisen sädehoidon jälkeen ei-pienisoluisen, asteen I keuhkosyövän liitännäishoitona. |
|
|
| Not yet recruiting | 2 | 216 | Europe | Durvalumab, MEDI4736, Concentrate for solution for infusion, Imfinzi | Sahlgrenska University Hospital, Astra Zeneca | Stage I Non-small cell lung cancer (NSCLC) that has been treated with Stereotactic Body Radiotherapy (SBRT). asteen I ei-pienisoluinen keuhkosyöpä, jonka sopivaksi hoitomuodoksi on arvioitu stereotaktinen sädehoito, Early stage, i.e. localized Non-small cell lung cancer that has been treated with high dose radiotherapy. asteen I ei-pienisoluinen keuhkosyöpä, jonka sopivaksi hoitomuodoksi on arvioitu stereotaktinen sädehoito, Diseases [C] - Cancer [C04] | | | | |
2019-002192-33: Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy- Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy |
|
|
| Not yet recruiting | 2 | 57 | Europe | Durvalumab, Solution for infusion, Imfinzi | Institut für Klinische Krebsforschung IKF GmbH, AstraZeneca GmbH | unresectable stage III NSCLC (Non–small-cell lung cancer), unresectable stage III NSCLC (Non–small-cell lung cancer), Diseases [C] - Cancer [C04] | | | | |
2018-003056-21: Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer. |
|
|
| Not yet recruiting | 2 | 76 | Europe | Olaparib, Cediranib, Durvalumab, Film-coated tablet, Concentrate for solution for injection/infusion | Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, AstraZeneca, CRUK Cambridge Centre | Surgically resectable renal cell cancer (Stage M0/M1), Surgically resectable renal cell cancer (Stage M0/M1), Diseases [C] - Cancer [C04] | | | | |
2018-002852-34: Durvalumab and Tremelimumab with microwave tumor ablation for unresectable locally advanced pancreatic cancer. |
|
|
| Not yet recruiting | 2 | 20 | Europe | Tremelimumab, Durvalumab (Medi4736), MEDI1123, MEDI4736, Solution for infusion, Durvalumab | UZLeuven, AstraZeneca | Unresectable Locally Advanced Non Metastatic Pancreatic Cancer, Pancreatic Cancer, Diseases [C] - Cancer [C04] | | | | |
PrE0505, NCT02899195: Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma |
|
|
| Completed | 2 | 55 | US | Durvalumab, MEDI4736 | PrECOG, LLC., AstraZeneca | Mesothelioma, Pleural Mesothelioma | 02/20 | 06/23 | | |
|
|
2018-001066-42: Durvalumab plus tremelimumab for progressive, refractory advanced thyroid carcinoma Durvalumab más tremelimumab para el carcinoma tiroideo avanzado, resistente al tratamiento y progresivo |
|
|
| Not yet recruiting | 2 | 84 | Europe | Durvalumab, Tremelimumab, MEDI4736, Tremelimumab, Solution for infusion, IMFINZI | Spanish Group of Neuroendocrine Tumors (GETNE), AstraZeneca | Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary,follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC).Advanced medullary thyroid carcinoma (MTC)Advanced anaplastic thyroid cancer (ATC) Carcinoma de tiroides diferenciado, avanzado, refractario al yodo radiactivo, incluyendo carcinoma tiroideo papilar, folicular, de células de Hürthle y poco diferenciado (CDT).Carcinoma medular de tiroides (CMT) avanzado.Cáncer anaplásico de tiroides (CAT) avanzado., Thyroid cancer Cáncer de tiroides, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 301 | Canada, RoW | Durvalumab, Tremelimumab, Platinum-Based Drug | Canadian Cancer Trials Group, AstraZeneca, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, National Health and Medical Research Council, Australia | Lung Cancer Metastatic | 02/20 | 12/24 | | |
2019-004366-18: Phase II study to evaluate MAintenance therapy with olaparib or selumetinib plus durvalumab according to BRCAness and KRAS somatic status Personalized in metastatic Pancreatic Adenocarcinoma patients |
|
|
| Not yet recruiting | 2 | 307 | Europe | durvalumab, olaparib 100mg tablet, OLAPARIB 150mg tablet, selumetinib, MEDI4736, AZD2281, AZD6244 blue 25 mg capsule, Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Lynparza 100 mg film-coated Tablet, Lynparza 150 mg film-coated Tablet | GERCOR, Astra Zeneca | Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Diseases [C] - Cancer [C04] | | | | |
2019-004284-51: Does immunotherapy (durvalumab) accumulate in the tumors of patients with lung cancer receiving chemotherapy together with radiotherapy. |
|
|
| Not yet recruiting | 2 | 10 | Europe | Injection, Imfinzi | Amsterdam UMC, VU University Medical Center, AstraZeneca | Lung cancer, NSCLC, lung cancer, Diseases [C] - Cancer [C04] | | | | |
NCT03046862: Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 31 | RoW | Durvalumab, MEDI4736, Tremelimumab, Gemcitabine, Cisplatin | Seoul National University Hospital | Biliary Tract Neoplasms | 05/20 | 12/24 | | |
CADMUS, ChiCTR2000033558: A Phase II, Multicenter, Single Arm Study to Determine the Efficacy of SBRT in Combination With Durvalumab Synchronous Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) |
|
|
| Not yet recruiting | 2 | 81 | China | Imfinzi (durvalumab) - AstraZeneca | Cancer Diagnosis and Treatment Center of the Sixth Medical Center of PLA General Hospital | Extensive Small-Cell Lung Cancer;SCLC;Oncology;Extensive stage SCLC | | | | |
2018-003048-22: A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition Eine Phase II Studie zur Evaluation der Sicherheit und Wirksamkeit von Durvalumab in Kombination mit der standard neoadjuvanten Therapie sowie zur Evaluation von Durvalumab +/- Tremelimumab bei Patienten mit lokal fortgeschrittenem Adenokarzinom des Ösophagus und zusätzlich Evaluation von Biomarkern, die eine Ansprechen auf Immuncheckpoint Inhibitoren vorhersagen könnten |
|
|
| Not yet recruiting | 2 | 56 | Europe | Durvalumab, Tremelimumab, Solution for injection, Imfinzi® | Universität zu Köln, AstraZeneca Ab | locally advanced esophageal adenocarcinoma lokal fortgeschrittenes Adenokarzinom des Ösophagus, cancer of the esophagus lokal fortgeschrittenes Adenokarzinom der Speiseröhre, Diseases [C] - Cancer [C04] | | | | |
BALTIC, NCT02937818 / 2016-001202-42: A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer |
|
|
| Completed | 2 | 72 | Europe, RoW | Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib | AstraZeneca | Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma | 06/20 | 11/23 | | |
|
BOLD, NCT04015739: Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse |
|
|
| Active, not recruiting | 2 | 74 | Europe | Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination, Experimental treatment | ARCAGY/ GINECO GROUP | Epithelial Ovarian Cancer, Relapse | 06/20 | 01/24 | | |
NCT03490760: Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas |
|
|
| Terminated | 2 | 9 | US | Durvalumab, Radiation Therapy | Baptist Health South Florida, AstraZeneca | Adenocarcinoma of the Pancreas | 07/20 | 07/20 | | |
CCTG PA.7, NCT02879318: Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 180 | Canada | Gemcitabine, Nab-paclitaxel, Durvalumab, Tremelimumab | Canadian Cancer Trials Group, AstraZeneca | Pancreatic Adenocarcinoma | 08/20 | 12/24 | | |
2019-004336-31: This is a phase II, open-label, multi-centre study to determine the safety and tolerability of durvalumab in patients with non-small cell lung cancer who were treated with radiation therapy but are ineligible for chemotherapy Il s'agit d'une étude de phase 2 internationale, multicentrique, à un seul groupe, en ouvert visant à évaluer l'activité clinique du durvalumab chez des patients atteints de CPNPC de stade III non résécable qui sont considérés comme non éligibles à la chimiothérapie. |
|
|
| Not yet recruiting | 2 | 150 | Europe | Durvalumab, MEDI4736, Concentrate for solution for infusion, CellCept 250 mg capsule, Remicade | AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB | Patients with Stage III unresectable Non-small cell lung cancer (NSCLC), who have an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2 and who are treated with radiotherapy but are ineligible for chemotherapy patients atteints de CPNPC de stade III non résécable qui sont considérés comme non éligibles à la chimiothérapie, A specific type of lung cancer type spécifique de cancer du poumon, Diseases [C] - Cancer [C04] | | | | |
2020-001028-32: Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract. |
|
|
| Not yet recruiting | 2 | 99 | Europe | Durvalumab, GEMCITABINE, CARBOPLATINE, CISPLATINE, MEDI4736, Solution for infusion | CHU DE NIMES, ASTRAZENECA | The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of divergent histologies (i.e. squamous-cell tumor, adenocarcinoma, small cell carcinoma, micropapillary variant) may be acceptable provided that there is an important prevalence (> 90%) of urothelial component., The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter., Diseases [C] - Cancer [C04] | | | | |
2019-004597-26: A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with Y-90 SIRT for intermediate stage HCC - IMMUWIN Eine Phase-II-Studie zur Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit Y-90 SIRT bei Patienten mit Leberzellkarzinom im Zwischenstadium - IMMUWIN |
|
|
| Not yet recruiting | 2 | 54 | Europe | Durvalumab, Tremelimumab, Solution for infusion, IMFINZI | Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, AstraZeneca GmbH | Intermediate stage hepatocellular carcinoma (HCC), Intermediate stage hepatocellular carcinoma (HCC), Diseases [C] - Cancer [C04] | | | | |
SOGUG, NCT03702179 / 2017-003159-44: Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach |
|
|
| Active, not recruiting | 2 | 32 | Europe | Durvalumab, MEDI4736, Tremelimumab, Radiotherapy | Spanish Oncology Genito-Urinary Group, AstraZeneca, MFAR | Invasive Bladder Cancer | 09/20 | 12/22 | | |
2019-001471-36: Prime RT - using chemotherapy and radiotherapy to charge the immune system making immunotherapies more effective in boosting anti-cancer immune responses in rectal cancer |
|
|
| Not yet recruiting | 2 | 54 | Europe | Durvalumab, Oxaliplatin, Fluorouracil, Folinic Acid, capecitabine, Concentrate for solution for infusion, Solution for injection/infusion, Film-coated tablet, Durvalumab | NHS Greater Glasgow and Clyde, The University of Glasgow, , AstraZeneca | Rectal Cancer., Cancer of the lower end of the large bowel., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 154 | Europe, Canada, US, RoW | Durvalumab, Olaparib, Placebo | AstraZeneca | Urinary Bladder Neoplasms | 10/20 | 12/24 | | |
|
| Active, not recruiting | 2 | 433 | Europe, Japan, US, RoW | Tremelimumab, Durvalumab, MEDI4736, Bevacizumab | MedImmune LLC | Hepatocellular Carcinoma | 11/20 | 03/25 | | |
|
2018-002281-39: Bevacizumab, Olaparib and Durvalumab combination in patients with advanced epithelial ovarian cancer in relapse. Association de bevacizumab, d'Olaparib et de Durvalumab chez des patientes d'un cancer de l'ovaire épithélial avancé en rechute |
|
|
| Not yet recruiting | 2 | 63 | Europe | olaparib, Durvalumab, Biosimilar bevacizumab, AZD2281, MEDI4736, FKB238, Tablet, Concentrate for solution for infusion, Olaparib | ARCAGY-GINCO, Astrazeneca | Patients with high grade serous or high grade endometrioid or other high grade epithelial non mucinous ovarian tumor, with at least one previous line of platinum-taxane chemotherapy, and present with platinum resistant disease (PRR) or platinum-sensitive relapse (PSR), whatever the line of chemotherapy given at relapse. Patientes présentant une tumeur ovarienne séreuse ou endometrioïde de haut grade ou autre tumeur épithéliale non mucineuse de haut grade, ayant reçu au moins une ligne de traitement par chimiothérapie par platine-taxane et présentant une rechute soit résistante au platine (RPR), soit sensible au platine (RPS), quelle que soit la ligne de chimiothérapie donnée au moment de la rechute., Patients with advanced epithelial ovarian cancer in relapse Ptientes atteintes d'un cancer de l'ovaire épithélial avancé en rechute, Diseases [C] - Cancer [C04] | | | | |
2020-003440-92: Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric or gastroesophageal junction cancer with microsatellite instability. Studio con la combinazione di due farmaci immunoterapici come terapia prima della chirurgia o come terapia definitiva in pazienti con tumore gastrico o della giunzione gastro-esofagea operabile con instabilità dei microsatelliti. |
|
|
| Not yet recruiting | 2 | 31 | Europe | Durvalumab, Tremelimumab, [MEDI4736], [MEDI1123], Concentrate for solution for infusion | G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST, Fondazione GONO, AstraZeneca S.p.A. | The disease under clinical investigation is represented by resectable gastric or gastroesophageal junction (Siewert II-III) adenocarcinoma staged as cT = 2, any cN, or any cT, cN1-3 (TNM classification 8th edition), without distant metastases (cM0).The study requires central confirmation of tumor molecular status of microsatellite instability and dMMR by both immunohistochemistry and multiplex polymerase chain reaction, and EBV-negative status by silver-in situ hybridization. La malattia oggetto di studio clinico è costituita dall'adenocarcinoma gastrico o della giunzione gastroesofagea (Siewert II-III) resecabile, stadiato clinicamente secondo la classificazione TNM (8° edizione) come cT = 2, ogni cN, oppure ogni cT, cN1-3, senza evidenza di metastasi a distanza (cM0). E' necessaria conferma centralizzata di instabilità microsatellitare mediante immunoistochimica e reazione polimerasica a catena, e status EBV-negativo mediante ibridizzazione in situ argentica., Cancer in the stomach or in the junction between the stomach and the oesophagus, without metastases in other organs and surgically resectable, with microsatellite instability and no EBV infection. Tumore nello stomaco o nella giunzione tra stomaco ed esofago, senza metastasi in altri organi e asportabile chirurgicamente, con instabilità dei microsatelliti e assenza di infezione da EBV., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 401 | Europe, Japan, US, RoW | Durvalumab, MEDI4736 (Durvalumab), Placebo for Olaparib, Placebo, Olaparib, AZD2281 (Olaparib), Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin | AstraZeneca | Non-small Cell Lung Cancer NSCLC | 01/21 | 09/24 | | |
|
|
2018-003832-57: Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, HER2-negative breast cancer patients. |
|
|
| Not yet recruiting | 2 | 166 | Europe | Durvalumab, Olaparib, Fulvestrant, Goserelin, MEDI4736, Solution for infusion, Tablet, Solution for injection, Implant in pre-filled syringe, Faslodex, ZOLADEX | UNICANCER, Laboratories AstraZeneca | ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status., ER-positive and HER2-negative metastatic or locally advanced breast cancer, Diseases [C] - Cancer [C04] | | | | |
16-C-0135, NCT02821754: A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) |
|
|
| Completed | 2 | 54 | US | Durvalumab, Imfinzi, Tremelimumab, Ticilimumab, Trans-arterial Catheter Chemoembolization (TACE), TACE, Radiofrequency Ablation (RFA), RFA, Cryoablation, Cryosurgery | National Cancer Institute (NCI) | Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer | 02/21 | 12/22 | | |
| Not yet recruiting | 2 | 173 | Europe | DURVALUMAB, TAZEMETOSTAT, MEDI4736, EPZ-6438 ; E7438, Concentrate for solution for infusion, Tablet, IMFINZI, TAZVERIK | Institut Bergonié, AstraZeneca, PHRC-I | Advanced solid tumor, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 101 | Europe | Durvalumab, Tremelimumab, Cisplatin-based neoadjuvant chemotherapy, Standard of care (SoC) | Fundacion CRIS de Investigación para Vencer el Cáncer, AstraZeneca, Apices Soluciones S.L. | Bladder Cancer | 04/21 | 04/23 | | |
NCT04089553: An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer |
|
|
| Completed | 2 | 59 | US | AZD4635, Oleclumab, MEDI9447, Durvalumab, Imfinzi, MEDI4736 | AstraZeneca | Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 06/21 | 04/23 | | |
NCT03377400: Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer |
|
|
| Active, not recruiting | 2 | 40 | RoW | Durvalumab, tremelimumab, 5FU, Cisplatin | Samsung Medical Center | Esophageal Squamous Cell Carcinoma | 06/21 | 12/21 | | |
NCT03450967: Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC |
|
|
| Active, not recruiting | 2 | 31 | RoW | Durvalumab Plus Tremelimumab | Samsung Medical Center | Head and Neck Squamous Cell Carcinoma | 06/21 | 03/22 | | |
2020-006106-23: Preoperative durvlumab treatment for patients with early small triple negative breast cancer |
|
|
| Not yet recruiting | 2 | 200 | Europe | MEDI4736, Solution for infusion, IMFINZI | Gustave Roussy, Astra Zeneca | Untreated operable small triple negative breast cancer, Untreated triple negative breast cancer, Diseases [C] - Cancer [C04] | | | | |
ACTRN12618000109202: A Phase II Study of Durvalumab and Tremelimumab in combination with Neoadjuvant Carboplatin and Paclitaxel in newly diagnosed women with advanced high grade Serous Ovarian, Fallopian Tube and Peritoneal Cancers “iPRIME”. |
|
|
| Completed | 2 | 75 | | | Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia New Zealand Gynaecological Oncology Group (ANZGOG) | Ovarian cancer, Fallopian tube cancer, Peritoneal cancer | | | | |
| Active, not recruiting | 2 | 55 | Europe | PARP inhibitor and Anti-PD-L1, olaparib, durvalumab, PARP inhibitor, Anti-PD-L1 Monoclonal Antibody | Leiden University Medical Center, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, Maastricht University Medical Center, The Netherlands Cancer Institute, Radboud University Medical Center, University Medical Center Groningen, UMC Utrecht, AstraZeneca | Endometrial Neoplasms, Uterine Neoplasms, Endometrium Cancer | 08/21 | 08/21 | | |
2020-004738-39: DOVACC.A study investigating the effect of the medication: olaparib, durvalumb and UV1 as maintenance therapy for patients with Recurrent Ovarian Cancer. |
|
|
| Ongoing | 2 | 184 | Europe | UV1, Imfinzi (Durvalumab), LEUKINE, Powder for solution for injection, Tablet, Infusion, Lynparza, Imfinzi, Leukine | Nordic Society of Gynaecological Oncology - Clinical Trial Unit, Ultimovacs, AstraZeneca | Ovarian cancer, Ovarian cancer, Diseases [C] - Cancer [C04] | | | | |
2021-001713-37: Phase II, two-cohorts, randomized trial comparing standard of care versus immune-based combination in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab Studio di fase 2 con due coorti, randomizzato, di confronto tra terapia standard e combinazioni di chemioimmunoterapia in pazienti con carcinoma polmonare non a piccole cellule recidivato dopo chemioradioterapia e durvalumab per malattia al terzo stadio |
|
|
| Not yet recruiting | 2 | 176 | Europe | Olaparib, Durvalumab, [D0810000000], [MEDI4736], Tablet, Powder for concentrate for solution for infusion | FONDAZIONE RICERCA TRASLAZIONALE (FORT), (1) AstraZeneca S.p.A. | non-small-cell lung cancer (NSCLC) carcinoma polmonare non a piccole cellule, non-small-cell lung cancer (NSCLC) carcinoma polmonare non a piccole cellule, Diseases [C] - Cancer [C04] | | | | |
NCT02953457: Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation |
|
|
| Active, not recruiting | 2 | 40 | US | Durvalumab, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Laboratory Biomarker Analysis, Olaparib, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Roswell Park Cancer Institute, AstraZeneca | BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma | 09/21 | 10/24 | | |
| Completed | 2 | 120 | Europe | Durvalumab + Tremelimumab + RT | University of Erlangen-Nürnberg Medical School | Locally Advanced Head and Neck Squamous Cell Carcinoma | 09/21 | 02/24 | | |
2020-001588-10: Adjuvant therapy in stage IV colorectal cancer patients NED terapia adiuvante nei pazienti con adenocarcinoma del colon-retto in stadio IV NED |
|
|
| Not yet recruiting | 2 | 170 | Europe | DURVALUMAB, REGORAFENIB (STIVARGA), [EMEA/H/C/4771], [BAY 73-4506], Concentrate for solution for injection/infusion, Modified-release tablet, STIVARGA | IRCCS-A.O.U. SAN MARTINO-IST, AIRC, Astra Zeneca, Bayer | stage IV colorectal cancer patients with no evidence of disease (NED) nei pazienti con adenocarcinoma del colon-retto in stadio IV senza evidenza di malattia (NED), colorectal adenocarcinoma adenocarcinoma del colon retto, Diseases [C] - Cancer [C04] | | | | |
2020-003925-42: Study on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer |
|
|
| Not yet recruiting | 2 | 84 | Europe | Tremelimumab, Durvalumab, TheraSphere, Solution for infusion, Implant, TheraSphere | Clinics of Munich University LMU, Astra Zeneca, Boston Scientific | Patients with hepatocellular cancer, not amenable to curative surgical or ablation treatment., tumor of the liver which cannot be removed by surgery or other ablation techniques, Diseases [C] - Cancer [C04] | | | | |
2019-004025-24: Study on the activity and safety of a treatment with an antibody in association with chemotherapy in a first phase, and with radiotherapy in a second phase, in patients with advanced non-small cell lung cancer of large volume Étude sur l'activité et la sécurité d'un traitement avec un anticorps en association avec une chimiothérapie dans une première phase, et avec une radiothérapie dans une seconde phase, chez des patients atteints de cancer du poumon non à petites cellules avancé de grand volume |
|
|
| Not yet recruiting | 2 | 65 | Europe | Durvalumab, [Durvalumab], Solution for infusion, IMFINZI (50 mg/mL concentrate for solution for infusion, vial of 10 mL of concentrate) | IRCCS - ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, AstraZeneca | Locally advanced non-small cell lung cancer in stage III Cancer des poumons non à petites cellules localement avancé au stade III, Advanced lung cancer Cancer des poumons à un stade avancé, Diseases [C] - Cancer [C04] | | | | |
2021-001203-32: STUDY OF COMBINATION OF IMMUNE CHEMOTHERAPY AND RADIOTHERAPY IN PATIENTS WITH INOPERABLE LUNG CANCER Studio di combinazione di immunochemioterapia e radioterapia in pazienti con tumore polmonare inoperabile |
|
|
| Not yet recruiting | 2 | 45 | Europe | durvalumab, [MEDI4736], Concentrate for solution for injection/infusion | FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO, AstraZeneca | stage III unresectable non-small cell lung cancer (NSCLC) carcinoma del polmone non a piccole cellule (NSCLC) di stadio III non resecabile, stage III unresectable non-small cell lung cancer (NSCLC) carcinoma del polmone non a piccole cellule (NSCLC) di stadio III non resecabile, Diseases [C] - Cancer [C04] | | | | |
NCT03871153: Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer |
|
|
| Terminated | 2 | 7 | US | Durvalumab, Imfinzi, Paclitaxel, Taxol, Carboplatin, Platinol, Radiation, Surgical Resection | Greg Durm, MD, AstraZeneca, Indiana University School of Medicine | Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer | 10/21 | 03/22 | | |
2021-002040-78: Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours Seguridad, farmacocinética y actividad clínica de AZD0171 en combinación con durvalumab y quimioterapia en tumores sólidos localmente avanzados o metastásicos |
|
|
| Not yet recruiting | 2 | 115 | Europe | AZD0171, Durvalumab, AZD0171, MEDI4736, Concentrate for solution for infusion, IMFINZI™ | AstraZeneca AB, AstraZeneca AB | Pancreatic ductal adenocarcinoma Adenocarcinoma ductal pancreático, Pancreatic Cancer Cáncer pancreático, Diseases [C] - Cancer [C04] | | | | |
NCT03237377: Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 9 | Canada, US | Durvalumab, [MEDI4736], Tremelimumab, [CP-675 206], Thoracic Radiation, lobectomy, Standard of care adjuvant chemotherapy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca | Non-Small Cell Lung Cancer | 11/21 | 05/25 | | |
2020-005101-12: A clinical trial to test the feasibility of a treatment with Olaparib (cohort A) or Olaparib in combination with Durvalumab (cohort B) given to patients with ovarian cancer during the time slot between diagnosis and primary debulking surgery. |
|
|
| Not yet recruiting | 2 | 60 | Europe | Olaparib, Durvalumab, AZD2281, KU-0059436, MEDI4736, Tablet, Concentrate for concentrate for solution for infusion, Lynparza, Imfinzi | AGO Research GmbH, AstraZeneca GmbH | Patients with presumed and previously untreated advanced stage ovarian cancer planned to undergo laparoscopy for histologic diagnosis and treatment planning., Patients with presumed and previously untreated advanced stage ovarian cancer planned to undergo laparoscopy for histologic diagnosis and treatment planning, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 18 | Europe | Durvalumab, MEDI4736 | Simon C Pacey, MD, AstraZeneca | Oesophageal Cancer | 11/21 | 06/24 | | |
NCT02788773: Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer |
|
|
| Active, not recruiting | 2 | 52 | Canada | Durvalumab, Tremelimumab | Canadian Cancer Trials Group, AstraZeneca | Prostate Cancer | 11/21 | 12/24 | | |
NCT03572400: Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 71 | RoW | Gemcitabine, Durvalumab | Do-Youn Oh, AstraZeneca | Pancreatic Cancer | 12/24 | 12/24 | | |
ChiCTR2000040962: A phase II study to evaluate the efficacy and safety of Durvalumab combined with chemotherapy in the whole process management of non-small cell lung cancer |
|
|
| Recruiting | 2 | 30 | China | Durvalumab | Air Force Medical Center ; Air Force Special Medical Center, self-raised | Patients with driver gene (EGFR/ALK/ROS1) -negative, unresectable stage II-IIIA (N2) NSCLC | | | | |
PALEO, NCT06290505: A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: Study |
|
|
| Recruiting | 2 | 54 | RoW | Durvalumab, Imfinzi | Australasian Gastro-Intestinal Trials Group | Oesophageal Cancer | 07/27 | 01/28 | | |
NCT04224337: Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma |
|
|
| Active, not recruiting | 2 | 34 | RoW | Durvalumab + doxorubicin + ifosfamide | Seoul National University Hospital | Carcinoma, Non-Small-Cell Lung | 08/23 | 05/25 | | |
2020-005942-41: A multicenter phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) - DUPLE trial Studio multicentrico di fase II, a braccio singolo di durvalumab (MEDI 4736) con carboplatino ed etoposide per 4 cicli seguiti da durvalumab di mantenimento in pazienti con carcinoma neuroendocrino a grandi cellule (LCNEC) del polmone - Studio DUPLE- GOIRC-05-2020 |
|
|
| Not yet recruiting | 2 | 49 | Europe | Carboplatino, Etoposide, Durvalumab, [Carboplatino], [Etoposide], [MEDI4736], Concentrate for solution for infusion, Concentrate for solution for injection/infusion, CARBOPLATINO AHCL - 50 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 5 ML, ETOPOSIDE TEVA - 1 FLACONE 5 ML 20MG/ML, CARBOPLATINO AHCL - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 60 ML, CARBOPLATINO AHCL - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 15 ML, ETOPOSIDE TEVA - 1 FLACONE 10 ML 20MG/ML | GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC), Astrazeneca | treatment-naïve patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) pazienti affetti da carcinoma neuroendocrino a grandi cellule (LCNEC) del polmone avanzato non pretrattati, treatment-naïve patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) pazienti affetti da carcinoma neuroendocrino a grandi cellule (LCNEC) del polmone avanzato non pretrattati, Diseases [C] - Cancer [C04] | | | | |
